A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization (SEEDS)

• ClinicalTrials.gov Identifier: NCT01157455
• Recruitment Status: Unknown
• First Posted: July 7, 2010
• Last Update Posted: July 12, 2010
• Sponsor: CCRF Consulting Co., Ltd.
• Information provided by: CCRF Consulting Co., Ltd.

Study Description

Brief Summary:

This is a prospective, multi-center registry to evaluate safety and effectiveness of the Everolimus Drug Eluting Stent for treatment coronary revascularization in Chinese patients with long lesion, small vessel or multi-vessel diseases.

Condition or disease	Intervention/treatment	Phase
Coronary Artery Diseases	Procedure: Everolimus Drug Eluting Stent; Drug: Aspirin; Drug: Clopidogrel; Drug: Heparin or Bivalirudin	Phase 4

Detailed Description:

Study Device:The XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) is a device/drug combination product consisting of either the MULTI-LINK VISION® Coronary Stent System or the MULTI-LINK MINI VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer. Design:A prospective, multi-center, registry that is designed to enroll Chinese patients with either Long Lesion, or Small Vessel or Multi-Vessel diseases. Purpose:To evaluate the safety and effectiveness of the XIENCE V® everolimus drug eluting stent for coronary revascularization of patients with either long lesion, or small vessel, or multi-vessel diseases. Enrollment:Approximately 1900 patients will be enrolled in at least 45 but up to 51 centers. Mainland China 41 up to 47 centers, Taiwan China 3 centers and Macao China 1 center. This registry is planned to enroll at least 50% of patients with multi-vessel disease. Primary Endpoint:Ischemia-driven Target Vessel Failure (TVF) which is a composite of cardiac death, myocardial infarction (Q and non-Q wave) and target vessel revascularization (TVR) at 12 months post-index procedure. Follow-Up Visits:30 days, 6 months, 12 months, and 24 months post index procedure.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 1900 participants
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Clinical Trial Program of a Medical Instrument Product
• Study Start Date: May 2010
• Estimated Primary Completion Date: March 2012
• Estimated Study Completion Date: June 2013

Arms and Interventions

Intervention Details:

• Procedure: Everolimus Drug Eluting Stent
  Implantation
  Other Names:

  • XIENCE(TM) V EECSS
  • XIENCE(TM) V stent system
• Drug: Aspirin
  Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
• Drug: Clopidogrel

  A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.

  75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy.

• Drug: Heparin or Bivalirudin
  During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.

Outcome Measures

Primary Outcome Measures :

1. TVF [ Time Frame: 12 months post-index procedure. ]
   Ischemia-driven Target Vessel Failure (TVF) which is a composite of cardiac death, myocardial infarction (Q and non-Q wave) and target vessel revascularization (TVR),12 months post-index procedure.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. The patient must be ≥18 of age; male or (non-pregnant and non-breast feeding) female.
2. Diagnosis of stable angina, unstable angina or silent ischemia (evidence of myocardial ischemia).
3. Target lesion is at least length ≥ 25mm (visual estimate); or the number of target lesion is ≥ 2; or target vessel diameter ≤ 2.75mm.
4. At least one target lesion with a diameter stenosis ≥70% (visual estimate)
5. Acceptable candidate for CABG;
6. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided written Notice of Informed Consent, appropriate Ethics Committee(EC); and the patient is willing to comply with specified follow-up evaluations.

Exclusion Criteria:

1. Patients have evidence of an Acute Myocardial Infarction within a week prior to the index procedure.
2. Patient has congenital heart disease, severe valve dysfunction, bridge vascular disease, severe heart failure (NYHA ≥ Ⅲ level), or left ventricular ejection fraction ≤ 30%.
3. Patient has undergone previous stenting anywhere within the previous 1 year.
4. Patient has a preoperative renal dysfunction: serum creatinine> 2.0mg/dl (176.82umol / L).
5. Patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated or in which patient will not be able to comply with dual antiplatelet therapy for at least 1 year;
6. Patient has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, Prasugrel, stainless steel alloy, cobalt chromium, rapamycin, styrene-butylene-styrene or poly-lactic acid (PLA) polymer, and/or contrast sensitivity that cannot be adequately premedicated; Patient is allergic to contrast agent Sirolimus.
7. Patient has other medical illness (e.g., cancer, known malignancy , congestive heart failure, organ transplant recipient or candidate) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy is less than 12 months.
8. Currently participating in another investigational drug or device study or patient in inclusion in another investigational drug or device study during follow-up
9. Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study; Patient has poor compliance with the judgment of the investigator and can not complete the study as required.
10. Patient who had heart transplant.

Contacts and Locations

Contacts

Contact: Bo Liu; 010-84094934 ext 816; bliu@ccrfmed.com

Locations

China

Fuwai Hospital; Recruiting

Beijing, China

Contact: Yuejin Yang yangyjfw@yahoo.com.cn

Contact: Bo Xu xubofuwai@gmail.com

Sponsors and Collaborators

CCRF Consulting Co., Ltd.

Investigators

• Principal Investigator: Yuejin Yang; Fuwai Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhang YJ, Zhao YL, Xu B, Han YL, Li B, Liu Q, Su X, Pang S, Lu SZ, Guo XF, Yang YJ. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study. Chin Med J (Engl). 2015 Mar 20;128(6):714-20. doi: 10.4103/0366-6999.152458.

Xu B, Yang YJ, Han YL, Lu SZ, Li B, Liu Q, Zhu GY, Cui JY, Li L, Zhao YL, Kirtane AJ; SEEDS Investigators. Validation of residual SYNTAX score with second-generation drug-eluting stents: one-year results from the prospective multicentre SEEDS study. EuroIntervention. 2014 May;10(1):65-73. doi: 10.4244/EIJV10I1A12.

• Responsible Party: Bo Liu, CCRF
• ClinicalTrials.gov Identifier: NCT01157455 History of Changes
• Other Study ID Numbers: SEEDS
• First Posted: July 7, 2010
• Last Update Posted: July 12, 2010
• Last Verified: April 2010

Keywords provided by CCRF Consulting Co., Ltd.:

Stent; Coronary artery diseases

Additional relevant MeSH terms:

Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Sirolimus; Everolimus; Heparin; Bivalirudin; Clopidogrel; Physiological Effects of Drugs; Fibrinolytic Agents; Fibrin Modulating Agents; Molecular Mechanisms of Pharmacological Action; Platelet Aggregation Inhibitors; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antineoplastic; Antifungal Agents; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents